Antitumor potential of Pleurotus ostreatus I-fraction in carcinomas with few therapeutic options.

HAAG L.M.; FERRONATO M.J.; IBARRA A.; CLEMENTE V.; CUESTAS J.M.; POTEMSKY P.D.; FERMENTO M.E.; COLO G.P.; PEDERSOLI A.; VITALE C,; FACCHINETTI M.M.; ALONSO E.N.; CURINO A. C.

Mar del Plata

Congreso; LXVIII Reunión Anual de la Sociedad Argentina de Investigación clínica (SAIC).; 2023

Sociedad Argentina de Investigación clínica (SAIC).

ANTITUMOR POTENTIAL OF PLEUROTUS OSTREATUS I-FRACTION IN CARCINOMAS WITH FEW THERAPEUTIC OPTIONS.Haag, LM(1), Ferronato MJ(1,2), Ibarra A(1,2), Clemente V(1,2), Cuestas JM(3), Postemsky PD(4), Fermento ME(1,2), Coló GP(1,2), Vitale C(5), Pedersoli AP(1), Curino AC(1,2), Facchinetti MM(1,2), Alonso EN(1,2).(1)Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Universidad Nacional del Sur (UNS)-CONICET, Bahía Blanca, CP 8000, Argentina. (2) Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS), Bahía Blanca, CP 8000, Argentina. (3) Laboratorio de Ecosistemas Naturales y Agropecuarios (LENA) (CIC/UNS), Bahía Blanca, CP 8000, Argentina. (4) Laboratorio de Biotecnología Hongos Comestibles y Medicinales, Centro de Recursos Naturales Renovables de la Zona Semiárida (CERZOS), Universidad Nacional del Sur (UNS)-CONICET, Bahía Blanca, CP 8000, Argentina. (5) Laboratorio de Química Orgánica, Departamento de Química, Universidad Nacional del Sur (INQUISUR), Bahía Blanca, CP 8000, Argentina.Pleurotus ostreatus is an edible mushroom recognized by the Argentine Food Code. The antitumor activity of its polysaccharides, free or bound to proteins, has been demonstrated on different types of cancer. However, this potential in Triple-Negative Breast Cancer (TNBC) and Head and Neck Squamous Cell Carcinoma (HNSCC) is unknown. Therefore, our objective is to determine the direct antitumor activity of I-Fraction: a polysaccharide-enriched extract obtained from P. ostreatus in TNBC and HNSCC. Previously, we reported that I-Fraction decreases the viability of 4T1 cells (TNBC-murine) starting at 2.5 mg/mL and 24 h of treatment. In the present work, by crystal violet assay, we demonstrated that this effect is also displayed on MDA-MB-231 cells (TNBC-human) starting at 2.0 mg/mL and 48 h of treatment (p